Venus Remedies soars on getting marketing authorization in Indonesia for Ceftazidime + Avibactam
Venus Remedies is currently trading at Rs. 727.00, up by 15.75 points or 2.21% from its previous closing of Rs. 711.25 on the BSE.
The scrip opened at Rs. 682.00 and has touched a high and low of Rs. 727.00 and Rs. 682.00 respectively. So far 666 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 848.90 on 24-Dec-2025 and a 52 week low of Rs. 272.20 on 28-Jan-2025.
Last one week high and low of the scrip stood at Rs. 798.80 and Rs. 682.00 respectively. The current market cap of the company is Rs. 935.69 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 3.29% and 54.96% respectively.
Venus Remedies has received marketing authorisation in Indonesia for its antibiotic combination Ceftazidime + Avibactam, granted by the relevant Indonesian drug regulatory authority. This approval marks the first marketing authorisation for Ceftazidime + Avibactam for the company in lndonesla. The product is indicated for the treatment of serious infections caused by multi-drug-resistant gram-negative pathogens, including complicated intra-abdominal infections and complicated urinary tract infections.
This authorisation enables the company to commercialise the product in Indonesia through its existing distribution partnerships and is expected to enhance the company's presence in a strategically important market for anti-infective. The development is aligned with the company's strategy of expanding its footprint in South-East Asia and strengthening its portfolio of high-barrier-to-entry therapies.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
